<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03712280</url>
  </required_header>
  <id_info>
    <org_study_id>MNK61062107</org_study_id>
    <nct_id>NCT03712280</nct_id>
  </id_info>
  <brief_title>MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)</brief_title>
  <official_title>A Randomized, Open-Label, Phase 2a Comparator Study to Assess the Pharmacodynamics, Safety and Pharmacokinetics of Oral Administration MNK6106 (L-Ornithine Phenylacetate) Versus Rifaximin in Subjects With Hepatic Cirrhosis and a History of Prior Episodes of Hepatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main reason for this study is to see how the study drug interacts with the body.

      It will compare different doses of the study drug with a drug already in use.

      Participants will be adults with liver disease that has affected the brain in the past.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Actual">July 14, 2020</completion_date>
  <primary_completion_date type="Actual">July 14, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with a change in ammonia at Day 5</measure>
    <time_frame>at Day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events by the end of the trial</measure>
    <time_frame>within 15 days</time_frame>
    <description>End of trial is defined as 7 (+/-3) days after last study treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hepatic Cirrhosis</condition>
  <condition>Hepatic Encephalopathy (HE)</condition>
  <arm_group>
    <arm_group_label>Group A: MNK6106 2 grams (tid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 2 tablets of MNK6106 three times daily (tid) for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: MNK6106 4 grams (bid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 4 tablets of MNK6106 twice daily (bid) for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: MNK6106 4 grams (tid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 4 tablets of MNK6106 tid for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: Rifaximin 550 mg (bid)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive 1 tablet of rifaximin bid for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MNK6106</intervention_name>
    <description>1 gram tablet of MNK6106 for oral administration</description>
    <arm_group_label>Group A: MNK6106 2 grams (tid)</arm_group_label>
    <arm_group_label>Group B: MNK6106 4 grams (bid)</arm_group_label>
    <arm_group_label>Group C: MNK6106 4 grams (tid)</arm_group_label>
    <other_name>Study Drug</other_name>
    <other_name>L-Ornithine Phenylacetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>550 mg tablet of rifaximin for oral administration</description>
    <arm_group_label>Group D: Rifaximin 550 mg (bid)</arm_group_label>
    <other_name>Xifaxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        A potential participant may only be included if (at screening), he/she:

          1. Understands the study and has signed informed consent

          2. Is an adult, not pregnant or lactating

          3. Has cirrhosis of the liver

          4. Has had 1 instance of HE within 12 months

          5. Has hyperammonaemia defined as ≥37 μmol/L at screening

        Key Exclusion Criteria:

        A potential participant will be excluded if (at screening), he/she:

          1. Has contraindicated allergies

          2. Expects liver transplant within 1 month

          3. Has had a liver shunt within the last 3 months

          4. Has inadequate kidney, gastrointestinal, or cardiac function

          5. Has cancer, infection, lab abnormalities, or any other condition that, per protocol or
             in the opinion of the investigator might compromise:

               1. the safety and well-being of the participant or potential offspring

               2. the safety of study staff

               3. the analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Team Leader</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Empire Clinical Trials</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Clinical Professionals</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at the Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigacion (Research Foundation)</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Phenylacetic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

